CAR-T cells (TRP1)

CAR-T cells (TRP1) are an experimental chimeric antigen receptor (CAR) T-cell therapy designed to target Tyrosinase-related protein 1 (TRP1), a melanoma-associated antigen. Developed by researchers at the Medical University of South Carolina, these CAR-T cells are uniquely engineered to overexpress the transcription factor FOXP3. This 'regulatory T cell-inspired' modification is intended to enhance the fitness and persistence of effector T cells within the immunosuppressive tumor microenvironment (TME), which is typically characterized by hypoxia and lactate accumulation—conditions where FOXP3-expressing regulatory T cells normally thrive. Preclinical studies in melanoma models indicate that while FOXP3 overexpression may modestly reduce direct cytotoxicity in vitro, it significantly improves in vivo tumor control and protects the CAR-T cells from activation-induced cell death (AICD), particularly when administered as a total T cell population or in combination with supplemental CD4+ CAR-T cells.

Other names

TRP1 CAR-TTRP-1 CAR-TTRP 1 CAR-TTRP1-targeted CAR-T cellsTRP-1-targeted CAR-T cellsTRP 1-targeted CAR-T cellsCAR-FOXP3-T cellsCAR-FOXP-3-T cellsCAR-FOXP 3-T cellstotal CAR-FOXP3-T cells